Core Viewpoint - The recent private placement application by Huisheng Biological has been accepted by the Shenzhen Stock Exchange, but it faces significant criticism regarding the low issuance price and lack of specific investment projects, raising concerns about the interests of minority shareholders [1][2][3]. Company Summary - Huisheng Biological, a veterinary drug company, has been experiencing declining net profits since its IPO in 2020, with net profit dropping from 150 million yuan to a loss of 20.16 million yuan [6]. - The company's revenue has been increasing, but the net profit has been negatively impacted by the cyclical nature of the livestock industry and poor performance of previous investment projects [6][7]. - The company’s gross margin has decreased from 37% to 16.33%, and net margin has fallen from 19.31% to -1.65% due to various factors including declining product prices and rising costs [6]. Financing Details - The private placement will issue shares at a price of 9.19 yuan, significantly lower than the current market price of 20.68 yuan, which is only 44% of the market price [2][3]. - The maximum number of shares to be issued is 26,123,301, which could increase the controlling shareholders' stake to 47.92% [2][3]. - The total amount raised from this financing could reach 250 million yuan, but it is intended solely for replenishing working capital, raising questions about the necessity of the financing [3][4]. Investment Project Performance - Previous investment projects have largely failed to meet expected returns, with three out of five projects from the 2020 IPO not achieving their projected benefits [3][4]. - The company has faced challenges with its production capacity utilization and pricing, particularly in the case of the new products launched [4][6]. Industry Context - The veterinary drug industry is highly cyclical, with demand closely tied to the profitability of livestock farming [7]. - In the first quarter of 2024, Huisheng Biological reported a revenue increase of 92.96% and a net profit increase of 371.23%, attributed to improved cash flow in the livestock sector [7]. - However, the recent decline in pig prices raises uncertainty about whether the industry has truly recovered from its low point [7].

证券代码：001313 证券简称：粤海饲料 公告编号：2025-047 广东粤海饲料集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司经营范围变更情况 变更前 变更后 许可项目：饲料生产；兽药经营；水产 许可项目：饲料生产；兽药经营；水产养 养殖。（依法须经批准的项目，经相关部门 殖。（依法须经批准的项目，经相关部门批准 批准后方可开展经营活动，具体经营项目以 后方可开展经营活动，具体经营项目以相关部 相关部门批准文件或许可证件为准） 门批准文件或许可证件为准） 一般项目：畜牧渔业饲料销售；饲料原 广东粤海饲料集团股份有限公司（以下简称"公司"）于2025年7月7日召开第 四届董事会第二次会议，审议通过了《关于修改公司经营范围及相应修改 <公司章> 程>的议案》。现将相关事项公告如下： 根据公司战略规划，结合日常实际经营及业务发展需要，拟对公司经营范围进 行变更，并相应修订《公司章程》，具体内容如下： 一般项目：畜牧渔业饲料销售；饲料原料 料销售；饲料添加剂销售；肥料销售；货物 销售；饲料添加剂销售；肥料销售；货物进出 进出口；渔业机械 ...

证券代码：001313 证券简称：粤海饲料 公告编号：2025-046 广东粤海饲料集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东粤海饲料集团股份有限公司（以下简称"公司"）于2025年7月7日召开第 四届董事会第二次会议，审议通过了《关于以固定资产对全资子公司进行增资的议 案》。现将相关事项公告如下： 流、技术转让、技术推广；饲料原料销售；畜牧渔业饲料销售；生物饲料研发；农 业科学研究和试验发展；生物化工产品技术研发；自然科学研究和试验发展；饲料 添加剂销售；饲料添加剂生产；饲料生产；检验检测服务。 | 单位：元 | | --- | | 项目 | 2024 | 年 | 12 | 月 | 31 | 日（经审计） | 2025 年 | 3 | 月 | 31 | 日（未经审计） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资产总额 | | | | | 470,913.48 | | | | | 305,456.38 | | | 负责 ...

Core Points - Zhejiang Shengda Bio-Pharm Co., Ltd. is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][4] - The company was approved by the China Securities Regulatory Commission to issue 20 million shares of common stock to the public and was listed on the Shanghai Stock Exchange on August 23, 2017 [2][4] - The registered capital of the company is RMB 189,029,624 [3][4] - The company's business scope includes drug production, feed additives production, food additives production, and hazardous chemicals production, among others [4][5] Company Structure - The company is structured as a permanent joint-stock company with all assets divided into equal shares, and shareholders are liable for the company's debts only to the extent of their subscribed shares [3][4] - The company has established a party organization in accordance with the regulations of the Communist Party of China, which plays a political core role within the company [2][3] Share Issuance and Management - The shares of the company are issued in the form of stocks, with each share having a par value of RMB 1 [5][6] - The total number of shares issued by the company is 189,029,624, all of which are common shares [6][7] - The company cannot provide any financial assistance to individuals or entities purchasing its shares [6][7] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in shareholder meetings, as well as the obligation to comply with laws and regulations [12][13] - The company must maintain a shareholder register based on the records provided by the securities registration agency [12][13] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [43][44] - Shareholder meetings must be conducted in accordance with legal and regulatory requirements, and the company must provide legal opinions on the meeting's compliance [46][47] Voting and Resolutions - Resolutions at shareholder meetings can be classified as ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring a two-thirds majority [76][77] - The company must ensure that voting rights are exercised fairly, and any related party transactions must be disclosed and voted on without the participation of related shareholders [80][81]

Group 1 - The company announced the adjustment of its 2022 A-share issuance plan, reducing the total fundraising amount from a maximum of 19.9 billion to 10 billion [1] - The net proceeds after deducting issuance costs are intended for various projects, including a 220,000 tons/year lithium battery materials R&D integration project (500 million), a 100,000 tons/year liquid lithium salt project (130 million), a 11,000 tons/year additive project (70 million), and to supplement working capital (300 million) [1] - Other aspects of the plan remain unchanged [1]

同时，陕西出入境边防检查总站协助推动榆林榆阳机场对外开放列入国家2025年度口岸开放审理计 划。榆林榆阳机场成为今年列入审理计划的唯一一个内陆省份口岸，也是唯一一个航空口岸。目前，榆 林榆阳机场T1航站楼改造土建施工已基本完成，口岸查验基础设施已进入采购程序，各项准备工作正 有条不紊地推进。 "随着暑期出行旺季到来及国际航班进一步恢复，下半年西安口岸出入境客流有望继续保持高位运 行。"陕西出入境边防检查总站执勤一队队长王虹说。（记者：霍海澎 苏欣雨） 陕西与美国怀俄明州青年开展友好交流 西安口岸上半年出入境旅客同比增长65% 7月1日，记者从陕西出入境边防检查总站获悉：今年上半年，陕西出入境边防检查总站查验出入境 人员95万余人次、航班7000余架次，同比分别增长65%、68%。其中，查验往来中亚国家人员7.8万余人 次、航班700余架次，同比分别增长40%、19%。 据了解，今年上半年，从西安咸阳国际机场入境的外国人超12万人次，同比增长131%。其中，使 用单方面免签、互免签证以及过境免签等政策入境外国人9.2万余人次，同比增长349%。 今年以来，陕西出入境边防检查总站立足西安咸阳国际机场国际枢纽定位， ...

| 证券代码：603065 证券简称：宿迁联盛 公告编号：2025-040 | | --- | | 宿迁联盛科技股份有限公司 | | 关于为子公司提供担保及接受子公司担保的进展公 | | 告 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | 重要内容提示： | | ? 担保对象及基本情况 | | 被担保人名称 烟台新特路新材料科技有限公司 | | 本次担保金额 1,000.00 万元 | | 担保对 | | 象（一） 实际为其提供的担保余额 2,000.00 万元 | | 是否在前期预计额度内 ?是 □否 □不适用：_________ | | 本次担保是否有反担保 □是 ?否 □不适用：_________ | | 被担保人名称 宿迁联盛科技股份有限公司 | | 万元 | | 担保对 | | 象（二） 实际为其提供的担保余额 4,300.00 万元 | | 是否在前期预计额度内 ?是 □否 □不适用：_________ | | 对外担保逾期的累计金额（万元） 0.00 | | 截至本公告日上市公司及其控股 ...

7月1日，记者从省食品药品安全委员会办公室获悉：省食品药品安全委员会办公室、省工信厅、省 农业农村厅等六部门近期印发《陕西省食品添加剂滥用问题综合治理方案》，全面加强从农田到餐桌全 过程食品添加剂监管。 省食品药品安全委员会办公室相关负责人表示，各地区、各相关部门要聚焦突出问题，强化协调联 动，对重点品种、重点环节、重点区域深挖细查。要强化风险排查和分析研判，加大重大案件查办、典 型案例曝光力度，有效遏制食品添加剂滥用行为。（记者：仵永杰） 全面加强社会共治，督促指导相关食品行业协会加强行业自律，组织行业企业作出规范使用食品添 加剂承诺，引导行业企业切实落实食品添加剂非必要不添加的使用原则。及时发布政策宣传、标准解 读、典型案例等信息，引导消费者理性认识食品添加剂。鼓励企业内部"吹哨人"及消费者对违法违规线 索进行投诉。 《方案》明确指出食品添加剂滥用问题综合治理重点任务：加强食用农产品从种植养殖环节到进入 批发、零售市场或者生产加工企业前（"三前"）环节使用具有防腐、保鲜功能的农药监管，开展相关食 用农产品风险监测。加强进口食品添加剂检验监管，加强相关化工产品、工业原料生产行业管理。 持续开展食品添加剂生产 ...

华盛锂电分析师会议 调研日期：2025年07月01日 调研行业：化学制品 参与调研的机构：东方财富证券、中哲物产、启赋资本、同巨投 资等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHIL ...

证券简称：圣达生物 证券代码：603079 浙江圣达生物药业股份有限公司 向特定对象发行A股股票 上市公告书 保荐人（主承销商） 二〇二五年六月 特别提示 一、发行数量及价格 二、本次发行股票预计上市时间 本次发行新增股份将于限售期届满后的次一交易日起在上海证券交易所上 市流通交易，如遇法定节假日或休息日，则顺延至其后的第一个交易日。 三、新增股份的限售安排 本次向特定对象发行股票完成后，发行对象认购的本次发行的股票自本次发 行结束之日起6个月内不得转让。 发行对象所取得的公司本次向特定对象发行的股票在锁定期内因送股、资本 公积转增股本等形式所衍生取得的股票亦应遵守上述股票锁定安排。上述锁定期 满后，将按中国证监会及上交所的有关规定执行。 如中国证监会或上交所对于上述锁定期安排有新的规定或要求，将按照监管 机构的规定或要求对上述锁定期安排进行修订并予执行。 释 义 在本上市公告书中，除非上下文另有所指，下列简称具有如下含义： 圣达生物、发行人、 指 浙江圣达生物药业股份有限公司 公司 本次发行、本次向特 浙江圣达生物药业股份有限公司本次向特定对象发行股票的 指 浙江圣达生物药业股份有限公司向特定对象发行 A ...